Scholarlink

<p>3D bioprinting has emerged as a promising preclinical technology to explore tumor cell biology, interaction with the microenvironment, and drug sensitivity. Current methods allow inclusion of several cell types within the bioprinted objects and may also be compatible with migration of immune cells within the object. 3D bioprinted tumor models have been shown to be more relevant for preclinical studies than classical 2D systems for a number of key parameters including cell morphology, cell-cell interactions, interaction with non-tumor cells, drug diffusion and sensitivity. As compared to other 3D models, bioprinting is applicable to a large variety of tumor cell lines at a relatively low cost and may be performed over a flexible period of time, ranging from a few days to several weeks. Bioprinting has also increasingly been applied to primary samples from cancer patients. In this review, we present the promises and technical hurdles yet to overcome in order for 3D bioprinting models to be fully exploited in preclinical modeling of cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

3D bioprinting for cancer modeling and drug screening

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月20日

查看全文
  • Aurélie Cadiou,
  • Eva-Laure Peiller Matera,
  • Nicolas Ellinger,
  • Lars Petter Jordheim,
  • Michael Duruisseaux,
  • Christophe Marquette,
  • Charles Dumontet

摘要

3D bioprinting has emerged as a promising preclinical technology to explore tumor cell biology, interaction with the microenvironment, and drug sensitivity. Current methods allow inclusion of several cell types within the bioprinted objects and may also be compatible with migration of immune cells within the object. 3D bioprinted tumor models have been shown to be more relevant for preclinical studies than classical 2D systems for a number of key parameters including cell morphology, cell-cell interactions, interaction with non-tumor cells, drug diffusion and sensitivity. As compared to other 3D models, bioprinting is applicable to a large variety of tumor cell lines at a relatively low cost and may be performed over a flexible period of time, ranging from a few days to several weeks. Bioprinting has also increasingly been applied to primary samples from cancer patients. In this review, we present the promises and technical hurdles yet to overcome in order for 3D bioprinting models to be fully exploited in preclinical modeling of cancer.